Fractionation — Dividing Radiation Doses Over Time

In clinical oncology, fractionation refers to the strategic scheduling and division of ionizing radiation. The underlying biological rationale relies on the four fundamental principles of radiobiology: repair of sublethal cellular damage, reassortment of cells within the cell cycle, repopulation of surviving cells, and reoxygenation of hypoxic tumour tissue.

Healthy human cells generally repair radiation-induced DNA damage more efficiently than malignant cells. By spacing out treatments into distinct fractions—typically administered once daily over a period of several weeks—clinicians exploit these differing repair capacities. This therapeutic window maximizes cumulative tumour destruction whilst minimizing long-term toxicity to adjacent normal organs.

Fractionation directly shapes your daily routine, overall treatment calendar, and symptom experience during radiation therapy. Understanding your specific fractionation schedule helps you plan transportation, work commitments, and family life around outpatient visits. It also explains why side effects often develop gradually rather than appearing immediately on the first day. Different fractionation schedules exist, such as standard fractionation, hypofractionation (fewer, larger doses), or hyperfractionation (smaller doses given multiple times a day). Discussing this schedule with your radiation oncologist ensures you understand the trade-offs between overall treatment duration, daily appointment times, and potential acute or chronic side effects.

Fractionation itself is a treatment delivery technique rather than a biological test or laboratory marker. However, planning a fractionation regimen requires sophisticated diagnostic imaging and medical physics calculations. Before treatment begins, patients undergo a simulation computed tomography (CT) scan, often accompanied by magnetic resonance imaging (MRI) or positron emission tomography (PET). Dosimetrists and medical physicists use these scans to map tumour boundaries and normal organ tolerances, calculating precisely how many fractions are needed to deliver the prescription dose safely.

Fractionation is a core concept across almost all malignancies managed with external beam radiotherapy. It is routinely used in breast cancer, where modern protocols frequently employ moderate hypofractionation to shorten total treatment times. It is equally central to the management of prostate cancer, lung cancer, head and neck carcinomas, rectal cancer, and cervical tumours. In brain tumours, such as glioblastoma or intracranial metastases, specialized fractionation schedules are selected to protect critical neurological structures.

The choice of fractionation directly determines the format and duration of radiation therapy. Standard fractionation typically delivers 1.8 to 2 Gray (Gy) per day, Monday through Friday, over five to seven weeks. Accelerated hypofractionation delivers larger daily doses, completing treatment in one to three weeks with comparable efficacy for suitable patients. In stereotactic body radiotherapy (SBRT), extreme hypofractionation delivers very high doses across just one to five sessions. Fractionation schedules are frequently combined concurrently with radiosensitising chemotherapy or sequential immunotherapy.